Abstract 755P
Background
Retifanlimab (ZynyzTM) is a programmed death receptor-1 (PD-1)–blocking antibody recently approved in the United States for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. POD1UM-101 (NCT03059823) is an ongoing first-in-human dose finding and cohort expansion study in patients with advanced solid tumours. We have previously reported significant clinical activity with safety for retifanlimab representative of the class in the MSI-H or dMMR endometrial cancer expansion cohort (Berton D, SITC 2021). We present final study results.
Methods
Eligible patients had histologically proven, unresectable recurrent/metastatic MSI-H or dMMR endometrial cancer, Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1, disease progression during or following 1 to ≤5 prior systemic treatments, measurable disease (per RECIST v1.1), and were naïve to prior immune checkpoint inhibitors. MSI-H and dMMR status were centrally confirmed. Patients received retifanlimab 500 mg every 4 weeks for up to 2 years. The primary study endpoint was safety. Confirmed best overall response and duration of response were evaluated by independent central reviewer (ICR).
Results
A total of 76 patients with centrally confirmed MSI-H (65 [85.5%]) or dMMR (11 [14.5%]) disease were enrolled, with the last patient initiating treatment on 29 December 2020. Median age was 67 (range 49–88) years, 70 (92%) had endometrioid histology, 67 (88%) had metastatic disease, and 61 (80%) had visceral metastases. Most patients had received prior radiotherapy (54 [71%]) or surgery (68 [90%]). All patients except for one, had received prior chemotherapy for advanced disease with 33 (43.4%) patients receiving ≥2 prior systemic therapies. The overall response rate by ICR was 43% (95% CI: 32–55). Final results for this cohort including safety and secondary efficacy endpoints will be presented.
Conclusions
Retifanlimab has shown notable clinical activity in previously treated MSI-H or dMMR endometrial cancer, which is consistent with other checkpoint immunotherapies.
Clinical trial identification
NCT03059823, EudraCT 2017-000865-63.
Editorial acknowledgement
Envision Pharma Group (Philadelphia, PA), funded by Incyte Corporation (Wilmington, DE).
Legal entity responsible for the study
Incyte Corporation (Wilmington, DE).
Funding
Incyte Corporation, Wilmington, DE.
Disclosure
P. Pautier: Financial Interests, Institutional, Other, Travel & Honoraria: AstraZeneca, MSD, Tesaro; Financial Interests, Institutional, Other, Travel: Novartis; Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Tesaro. D. Lorusso: Financial Interests, Institutional, Advisory Role, Consultancy: Novartis, PharmaMar; Financial Interests, Institutional, Advisory Board, and invited speaker: AstraZeneca, Clovis Oncology, Genmab, GSK, Immunogen, MSD, Seagen; Financial Interests, Institutional, Other, ENGOT trial with institutional support for coordination: Clovis Oncology, Corcept, Genmab, Immunogen, MSD; Financial Interests, Research Grant, Grant for founding academic trial: Clovis Oncology, GSK, MSD. C. Gennigens: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Advisory Role: GSK, Ispen, MSD; Financial Interests, Institutional, Other, Honoraria: AstraZencea, Bristol Myers Squibb, GSK; Financial Interests, Institutional, Other, Honoraria and Support for meetings and/or travel: Ispen, MSD, Pfizer, PharmaMar; Financial Interests, Institutional, Advisory Board: AstraZeneca, Bristol Myers Squibb, Eisai, GSK, Ispen, MSD. L. Gladieff: Financial Interests, Advisory Board: AstraZeneca, Clovis Oncology, GSK, MSD; Financial Interests, Other, Honoraria: AstraZeneca, GSK, MSD, PharmaMar, Roche ; Financial Interests, Funding, Congress funding: GSK, PharmaMar, Roche, Viatris. J. Bowman, C. Tian, M. Cornfeld: Financial Interests, Institutional, Full or part-time Employment: Incyte; Financial Interests, Institutional, Stocks/Shares: Incyte. T. Van Gorp: Financial Interests, Institutional, Advisory Board: AstraZeneca, GSK, MSD, Tubulis; Financial Interests, Institutional, Research Grant: Amgen, Roche, AstraZeneca; Financial Interests, Institutional, Invited Speaker: GSK. All other authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11